US-based autism and ADHD diagnostic firm wins $822k RDTI refund
TaxAn AI-powered diagnostic platform supporting the early diagnosis of autism and ADHD has secured an $800,000 tax refund for its research activities in Australia and abroad.
Last Thursday (8 January), US-founded diagnostic platform BlinkLab revealed it had received an $822,205 R&D tax incentive (RDTI) refund in Australia for its domestic clinical research initiatives and a US pilot study.
BlinkLab was established in 2021 by Princeton University neuroscientists who sought to develop a smartphone-based diagnostic platform for autism and ADHD. The company, which has a Perth office, was listed on the ASX in 2024.
“Funds received from the R&D Tax Incentive will be applied to support BlinkLab’s ongoing research and development activities, including continued clinical studies and broader product and regulatory development programs,” the firm said in a statement.
BlinkLab said it sought to provide an accessible diagnostic aid for clinicians assessing patients for autism and ADHD. Its smartphone-based app leveraged AI and machine learning to support early detection of autism.
The R&D refund is related to expenditure on the company’s US pilot study, as well as clinical research initiatives in Australia. This included a research collaboration with Monash University, which aimed to better understand underlying factors driving overlaps between autism and ADHD in hopes of improving diagnostic models.
The 2024 study aimed to pave the way towards more personalised autism and ADHD diagnoses for children through smartphone-based screening tests, Monash University said.
BlinkLab said these R&D activities had supported the development, validation and clinical investigation of the company’s smartphone-based assessment technology.